“CD200 expression is reported across most cancer types [...]”
BUFFALO, NY- February 7, 2023 – A new research perspective was published in Oncotarget's Volume 14 on February 4, 2023, entitled, “ The immunoregulatory protein CD200 as a potentially lucrative yet elusive target for cancer therapy .”
CD200 is an immunoregulatory cell surface ligand with proven pro-tumorigenic credentials via its ability to suppress CD200 receptor (CD200R)-expressing anti-tumor immune function. This definitive role for the CD200-CD200R axis in regulating an immunosuppressive tumor microenvironment has garnered increasing interest in CD200 as a candidate target for immune checkpoint inhibition therapy.
However, while the CD200 blocking antibody samalizumab is still in the early stages of clinical testing, alternative mechanisms for the pro-tumorigenic role of CD200 have recently emerged that extend beyond direct suppression of anti-tumor T cell responses and, as such, may not be susceptible to CD200 antibody blockade.
In this new research perspective, researchers Anqi Shao and David M. Owens from Columbia University Irving Medical Center summarized the current understanding of CD200 expression and function in the tumor microenvironment as well as alternative strategies for potential neutralization of multiple CD200 mechanisms in human cancers.
“In the future, unbiased genomic- and proteomic-based approaches may help to clarify these issues by identifying tumor-specific mechanisms of CD200 expression regulation across a variety of human cancers that may be leveraged for broader therapeutic benefit.”
DOI: https://doi.org/10.18632/oncotarget.28354
Correspondence to: David M. Owens
Email: do2112@cumc.columbia.edu
Keywords: CD200 receptor, oncoimmunology, immunotherapy, tumor microenvironment, immune checkpoint inhibition
About Oncotarget : Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
To learn more about Oncotarget , visit Oncotarget.com and connect with us on social media:
For media inquiries, please contact: media@impactjournals.com .
Oncotarget Journal Office
6666 East Quaker Str., Suite 1A
Orchard Park, NY 14127
Phone: 1-800-922-0957 (option 2)
###
Oncotarget
Commentary/editorial
People
The immunoregulatory protein CD200 as a potentially lucrative yet elusive target for cancer therapy
4-Feb-2023